Clinical trials: Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia
Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia
Testing a Reduced Conditioning Regimen FB2A2 Preceded by a Fractionated Radio-immunotherapy (RIT) With 90Y-Epratuzumab Before Allogeneic Stem Cell Transplantation for Patients With Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia
Determination of the maximum tolerated dose (MTD) of fractionated RIT with epratuzumab radiolabeled with yttrium-90 (90Y-epratuzumab) preceding a reduced conditioning regimen FB2A2 before allogeneic stem cell transplantation.
- Trial name
- EPRALLO (NCT02577094)
- Testing
- 90Y-DOTA-Epratuzumab IgG/Epratuzumab IgG, Busulfan, allogeneic stem cell transplantation.
- Sponsor
- Nantes University Hospital